GENERIC HIV CHARGE VIRALE IVD

HIV remains a major problem of public health, with nearly 40 million infected people worldwide.

WHO recommends facilitating access to diagnosis and treatment, in order to start antiretroviral therapy as early as possible for all infected people and thus limit the occurrence of life-threatening complications.

By stopping viral replication, treatments can improve the length and the quality of life of infected people.

Measuring the viral load by quantification of HIV-1 RNA allows the monitoring of the treatment effectiveness and the early switching of the therapy in case of treatment failure.

GENERIC HIV CHARGE VIRALE is an accurate test for the quantification of HIV-1 RNA from only 250 μL of plasma EDTA samples by targeting the highly conserved LTR region.

Automated extraction with the GenoXtract^®, in combination with GXT NA Extraction kits, provides highly purified nucleic acids for optimal PCR performance.

GENERIC HIV CHARGE VIRALE can easily be implemented in the routine analysis workflow using existing laboratory equipment, as the commonly available thermocyclers are validated with the assay. Particularly, the FluoroCycler^® XT provides fully automated analysis with FluoroSoftware^® XT-IVD generating results at a glance, in an easy-to-use, easy-to-interpret test report.

GenoXtract®, FluoroCycler® and FluoroSoftware® are registered trademarks of the Bruker group of companies.
GenoXtract® and FluoroCycler® XT, Legal manufacturer:  Hain Lifescience, Hardwiesenstrasse 1, 72147 Nehren, Germany

Read instructions for use and/or labelling of the product.
Please contact your local representative for availability in your country.
Not for sale in the USA, Brazil, Australia, Japan and Canada.